GlassScriptPhysician profile
Natalie Diaz
NPI 1871516492
$3,698.14
in general payments reported to CMS, 2019-2025
28 companies · $945 in 2025
The $945 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $266 · 2021: $296 · 2022: $503 · 2023: $694 · 2024: $796 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.35 | 2022-2025 | Botox, Ubrelvy |
| Medtronic, INC. | $530.87 | 2021-2025 | Percept PC Brainsense |
| Ipsen Biopharmaceuticals, INC | $429.90 | 2022-2025 | Dysport |
| Kyowa Kirin, INC. | $308.26 | 2019-2025 | Nourianz |
| Merz Pharmaceuticals, LLC | $289.37 | 2022-2025 | Xeomin |
| Insightec,INC | $206.78 | 2025 | Exablate |
| Boston Scientific Corporation | $181.20 | 2019-2021 | |
| Allergan, INC. | $177.04 | 2021-2022 | |
| Mdd US Operations, LLC | $172.94 | 2022-2025 | Gocovri, Gocovri |
| Acadia Pharmaceuticals INC | $145.45 | 2024-2025 | Nuplazid |
| Medtronic USA, INC. | $105.29 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $96.57 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $66.33 | 2020-2022 | |
| Ge Healthcare | $65.41 | 2022-2024 | |
| Depuy Synthes Sales INC. | $58.86 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.80 | 2025 | |
| Abbott Laboratories | $41.81 | 2025 | Infinity |
| Amneal Pharmaceuticals LLC | $36.60 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $33.79 | 2024 | Ultomiris |
| Springworks Therapeutics, INC. | $31.79 | 2025 | Gomekli |
| Caris Mpi, INC. | $28.33 | 2025 | Mi Cancer Seek |
| Neurocrine Biosciences, INC. | $23.38 | 2020 | |
| Microtransponder, INC. | $19.79 | 2023 | |
| Inspire Medical Systems, INC. | $18.76 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $16.03 | 2023 | Quviviq |
| Si-Bone, INC. | $15.71 | 2024 | |
| Nevro Corp. | $13.73 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.